15-12G - ObsEva SA (0001685316) (Filer)

8-K - ObsEva SA (0001685316) (Filer)

10-K - ObsEva SA (0001685316) (Filer)

EFFECT - ObsEva SA (0001685316) (Filer)

EFFECT - ObsEva SA (0001685316) (Filer)

EFFECT - ObsEva SA (0001685316) (Filer)

EFFECT - ObsEva SA (0001685316) (Filer)

EFFECT - ObsEva SA (0001685316) (Filer)

EFFECT - ObsEva SA (0001685316) (Filer)

EFFECT - ObsEva SA (0001685316) (Filer)

4 - ObsEva SA (0001685316) (Issuer)

4 - ObsEva SA (0001685316) (Issuer)

4 - ObsEva SA (0001685316) (Issuer)

3/A - ObsEva SA (0001685316) (Issuer)

3 - ObsEva SA (0001685316) (Issuer)

3 - ObsEva SA (0001685316) (Issuer)

3 - ObsEva SA (0001685316) (Issuer)

3 - ObsEva SA (0001685316) (Issuer)

3 - ObsEva SA (0001685316) (Issuer)

3 - ObsEva SA (0001685316) (Issuer)

SC 13D - ObsEva SA (0001685316) (Subject)

SC 13G/A - ObsEva SA (0001685316) (Subject)

SC 13D/A - ObsEva SA (0001685316) (Subject)

SC 13G/A - ObsEva SA (0001685316) (Subject)

SC 13G/A - ObsEva SA (0001685316) (Subject)

SC 13G/A - ObsEva SA (0001685316) (Subject)

ObsEva Files Year End 2022 Financial Statements Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 31, 2023 – ObsEva SA (SIX: OBSN / OTC Pink Market: OBSVF), a biopharmaceutical company developing and commercializing novel therapies to improve women's health, today published its U.S. Annual Report on Form 10-K for Fiscal Year 2022, including the U.S. GAAP financial results for year-end 2022. The U.S. Annual Report on Form 10-K can be accessed in the financial section of the Company's website, here or directly via the link here. ObsEva expects to publish its Swiss Annual Report to Shareholders, including the financial results for year end 20

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 15, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023. A Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on Nasd

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – February 24, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced a strategic reorganization that will consolidate operations in Switzerland so as to preserve cash, focus resources towards the development of nolasiban, a novel, oral oxytocin receptor agonist to improve in vitro fertilization success rates, and manage its out-licensed programs. As part of the reorganization, the Company is downsizing its US-based Executive Management team and will similarly propose a reduced Board of Directors at the

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 19, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that the competent court in Geneva, Switzerland has granted the Company's request to withdraw its moratorium considering that the Company is no longer over-indebted. The Company resolved its over-indebtedness due to the previously announced sale of all its rights to Ebopiprant to XOMA Corporation (XOMA) for an upfront payment of $15 million. Additionally, ObsEva is eligible to receive future milestone payments of up to approximately

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – December 14, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, announced today announced an update on its progress towards meeting Nasdaq's minimum stockholders' equity requirement. As previously announced, on August 19, 2022, the Company received a letter (the "Nasdaq Letter") from the Nasdaq Stock Exchange ("Nasdaq") notifying the Company that it is not in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Global Select Market. Nasdaq Listing Rule 5450(b)(1)(

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 9, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, announced today that its board of directors approved on December 8, 2022 an increase of its share capital through the issuance of 20,000,000 newly registered shares at an issue price of 1/13 of a Swiss Franc each. The 20,000,000 new shares, to be issued out of the company's authorized capital, will be fully subscribed for by ObsEva USA Inc., its 100% wholly owned subsidiary, and listed on the SIX Swiss Exchange on or around December 12, 2022. The tran

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 1, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))) ("ObsEva" or the "Company"), a biopharmaceutical company developing novel therapies for women's health, today reported financial results for the third quarter ended September 30, 2022 and provided a business update. "We are pleased to have neared the completion of a restructuring process that allowed us to generate an important influx of capital, positioned us to resolve our over-indebted position, and streamlined our cost structure," said Brian O'Callaghan, CEO of ObsEva. "We are now well-positioned to support the development of nolasiban, a

Sale of Ebopiprant royalty and milestone license to XOMA includes upfront payment of $15 million and future milestone payments of up to $98 millionThe sale proceeds are expected to enable ObsEva to resolve its current over-indebtedness position and to withdraw its pending Swiss moratorium proceedingsSale proceeds expected to position ObsEva to satisfy Nasdaq stockholders' equity requirement for continued public listingObsEva expects to have greater than one year of cash runway, providing strategic optionality Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – November 22, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))) ("ObsEva" or the "Company"), a bi

Transition of linzagolix program to Kissei Pharmaceutical Co., Ltd. substantially complete with approximately $16.0 million savings expected from assignment of program contracts, including $3.7 million of accounts payable assigned to date Company extends forbearance agreement with JGB through December 1, 2022Swiss court grants stay of moratorium proceedings through November 30, 2022, as ObsEva progresses restructuring initiatives Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – October 26, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing novel therapies for women's health, today announced that the transitio

-Linzagolix for uterine fibroids: Received confirmation of positive CHMP opinion for marketing authorization application; United States NDA PDUFA date in Q3:22- -Linzagolix for endometriosis: Reported positive topline results for linzagolix 200 mg with add-back therapy in the Phase 3 EDELWEISS 3 trial- -Linzagolix franchise: Announced licensing agreement with Theramex to support commercialization in Europe, in addition to relationship with Syneos Health to support commercialization in the United States- Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange                 GENEVA, Switzerland – May 17, 2022 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharma

GENEVA, Switzerland – May 12, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it plans to host a conference call on Tuesday, May 17, 2022, at 8:00 a.m. ET to discuss its financial results for the quarter ended March 31, 2022 and provide a business update. Individuals may participate via telephone by dialling (877) 300-8521 (domestic) or +1 (412) 317-6026 (international) and using conference ID 10166576. The webcast can be accessed live here and will also be accessible under "Events Calendar" in the investors section of ObsEva's website. The webcast will be archived on the company

-Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months- -Once daily linzagolix 75 mg without ABT demonstrated statistically significant improvement for dysmenorrhea versus placebo and showed improvement but did not meet the co-primary objective of reduction in non-menstrual pelvic pain at 3 months; also showed improvement in sec

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 13, 2023 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that Ernest Loumaye, MD, PhD, co-founder and member of the Board of Directors has been appointed as Interim Chairman following the resignation of Annette Clancy. It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. Additionally, the Company announced the appointment of Fabien de Ladonchamps as Chief

GENEVA, Switzerland May 19, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Annette Clancy as Chair of the Board of Directors at the Company's Annual General Meeting on May 18, 2022. Ms. Clancy has served as a member of ObsEva's Board of Directors since 2013 and was previously Chair from November 2013 to December 2016. Ms. Clancy succeeds Dr. Frank Verwiel, who had decided to step down from the role of Chair and retire from the Board of Directors, effective following the conclusion of the Annual General Meeting. "We could not be more pleased, or fortunate, to have

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – May 2, 2022 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Dr. Brandi Howard as Chief Clinical Officer and member of the company's Executive Committee, effective May 9, 2022. Dr. Howard, who brings to ObsEva more than 20 years of women's health expertise, will be responsible for the Company's clinical development and medical affairs strategy. She succeeds Dr. Elizabeth Garner, who will be departing the Company on May 6, 2022 to pursue a new opportunity. To help ensure a smooth tra

GENEVA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced the appointment of Katja Buhrer as Chief Strategy Officer and member of the company's Executive Committee, effective February 1, 2022. Ms. Buhrer will oversee a range of operational areas including corporate strategy, investor relations and public relations, and will contribute in other areas such as business development and alliance management. "We are thrilled to welcome Katja to ObsEva at this important time in the company's growth," said Brian O'Callaghan, Chief Executive Officer of ObsEva. "Katja

 Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – December 13, 2021 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the appointment of Will Brown as Chief Financial Officer and member of the company's Executive Committee, effective January 1, 2022. "We are thrilled to welcome Will, a highly accomplished biopharmaceutical executive with proven business development and financial acumen, to ObsEva's executive team," said Brian O'Callaghan, Chief Executive Officer of ObsEva. "This is an exciting time for ObsEva on the heels of the

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland November 22, 2021 – ObsEva SA (NASDAQ:OBSV, SIX: OBSN))), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced that Stephanie Brown has been selected to join its Board of Directors and will be proposed for election at the 2022 Annual General Meeting. In the meantime, and effective December 1, 2021, she will join the Board of Directors as an Observer. Ms. Brown brings valuable commercial expertise and industry insight to the Company. Jacky Vonderscher, Ph.D., has decided to step down from the Board effective 19 November 20

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange   GENEVA, Switzerland – September 30, 2021 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the appointment of Luigi Marro, as Chief Transformation Officer (CTO) and member of the company's Executive Committee, effective October 1, 2021. Mr. Marro will lead the Company's strategic Commercial Operational Readiness initiative. "We are delighted to welcome Luigi to ObsEva's executive team," said Brian O'Callaghan, Chief Executive Officer of ObsEva. "Luigi's comprehensive commercial experience in the re

Forbion Appoints Nanna Lüneborg as a General Partner - Brings extensive international investment and board experience in life sciences companies of all sizes including company creations, private venture deals and IPOs - Naarden, The Netherlands, 1 September 2021 – Forbion, a leading European life sciences venture capital firm, today announces the appointment of Nanna Lüneborg, PhD as a General Partner to work on the €360m Forbion Growth Opportunities Fund. Prior to joining Forbion, Nanna was a Partner at Novo Ventures and a key member of the European deal team focussing on late-stage biopharma investments across Europe. During her 10 years at Novo, Nanna was involved in numerous success

GENEVA, Switzerland and BOSTON, MA – May 6, 2021 – ObsEva SA (NASDAQ:OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women's reproductive health, today announced the appointment of Clive Bertram as Chief Commercial Officer and member of ObsEva's Executive Committee, effective May 10, 2021. Wim Souverijns has served as Chief Commercial Officer of ObsEva since November 2018 and will leave the Company on June 30, 2021 to pursue a new opportunity. He will work to ensure a smooth transition with Clive Bertram.  "We are delighted to welcome Clive to the executive team, especially at such an exciting time for the Company," said Br

H.C. Wainwright downgraded ObsEva from Buy to Neutral

Cantor Fitzgerald initiated coverage of ObsEva with a rating of Overweight and set a new price target of $6.00

Canaccord Genuity initiated coverage of ObsEva with a rating of Buy and set a new price target of $12.00

Aegis Capital initiated coverage of ObsEva with a rating of Buy and set a new price target of $12.00

HC Wainwright & Co. reiterated coverage of ObsEva with a rating of Buy and set a new price target of $15.00 from $17.00 previously

ObsEva SA (NASDAQ:OBSV, SIX: OBSN)))) today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023. A Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on Nasdaq.

ObsEva SA (NASDAQ:OBSV, SIX: OBSN))))), a biopharmaceutical company developing and commercializing novel therapies for women's health, today announced that it received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") on March 14, 2023, advising the Company that its securities are scheduled for delisting from The Nasdaq Capital Market and will be suspended at the opening of U.S. business on March 23, 2023. A Form 25-NSE will be filed with the Securities and Exchange Commission (the "SEC"), which will remove the Company's securities from listing and registration on Nasdaq. As previously announced, the Company received a notification letter on September 12, 2022 from Nasdaq ad

Gainers Provention Bio, Inc. (NASDAQ:PRVB) rose 262.7% to $24.30 in pre-market trading after Sanofi agreed to acquire the company for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. Tenax Therapeutics, Inc. (NASDAQ:TENX) rose 35.8% to $0.7737 in pre-market trading after gaining 23% on Friday. TRxADE HEALTH, Inc. (NASDAQ:MEDS) rose 15.9% to $0.40 in pre-market trading after dropping more than 5% on Friday. Meten Holding Group Ltd. (NASDAQ:METX) shares rose 15.5% to $0.2620 in pre-market trading. Myomo, Inc. (NYSE:MYO) rose 14.4% to $0.8471 in pre-market trading. Myomo is expected to report financial results for the three months and year ended Dec.

It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year. The Company's Interim Chief Executive Officer, Will Brown, will serve in that position until Mr. Ladonchamps' effective date of service on May 1, 2023.

It is expected that Dr. Loumaye will serve in this position until the 2023 Annual General Meeting of Shareholders, at which time he will be nominated for this position for the upcoming year.

Gainers Kimball International, Inc. (NASDAQ:KBAL) shares jumped 84.9% to $12.40 after HNI Corporation announced it will acquire the company for $485 million. Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) rose 40.9% to $2.48 after the company announced, in its Phase 1 study, FRTX-02 was generally safe and well tolerated within the potential therapeutic dose range, meeting the study's primary objectives. Arlo Technologies, Inc. (NYSE:ARLO) gained 38% to $4.95 after the company reported better-than-expected Q4 results and issued FY23 adjusted EPS guidance above estimates. Diversey Holdings, Ltd. (NASDAQ:DSEY) gained 37.3% to $8.16 after the company announced it will be acquired by Solenis

Gainers Fresh Tracks Therapeutics, Inc. (NASDAQ:FRTX) rose 51.1% to $2.66 in pre-market trading after the company disclosed topline results from single and multiple ascending dose parts of Phase 1 study of oral DYRK1A inhibitor FRTX-02. Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) rose 30.6% to $1.92 in pre-market trading after posting better-than-expected Q4 results. ObsEva SA (NASDAQ:OBSV) shares rose 27.5% to $0.1785 in pre-market trading after dropping 30% on Tuesday. Zymeworks Inc. (NASDAQ:ZYME) shares rose 18.8% to $9.46 in pre-market trading following strong quarterly sales. Maxeon Solar Technologies, Ltd. (NASDAQ:MAXN) rose 15.7% to $21.72 in pre-market trading following better-

Gainers Virax Biolabs Group Limited (NASDAQ:VRAX) jumped 99% to $1.3195 after the company announced an agreement for the distribution of an Avian Influenza A Virus real-time PCR test kit to the European market. EUDA Health Holdings Limited (NASDAQ:EUDA) surged 53.1% to $2.94. Assure Holdings Corp. (NASDAQ:IONM) jumped 41.2% to $6.86. Unicycive Therapeutics, Inc. (NASDAQ:UNCY) gained 36% to $1.69 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb. WW International, Inc. (NASDAQ:WW) shares gained 29.8% to $5.02 despite worse-than-expected Q4 revenue and Q1 guidance below estimates. The company also announced it wi

Gainers Unicycive Therapeutics, Inc. (NASDAQ:UNCY) shares surged 159% to $1.27 after the company announced a private placement of up to $130 million in gross proceeds to commercialize and launch Renazorb. BridgeBio Pharma, Inc. (NASDAQ:BBIO) shares jumped 59.5% to $17.34 after the company announced positive data for its phase 2 study of Infigratinib in Achondroplasia. Avalon GloboCare Corp. (NASDAQ:ALBT) shares gained 53.5% to $3.3330. Azul S.A. (NYSE:AZUL) gained 45.3% to $6.05 after the company announced a deal to reduce the immediate cash it must expend for leased property. Kala Pharmaceuticals, Inc. (NASDAQ:KALA) rose 28.3% to $21.49. HC Wainwright & Co. maintained Kala Pharmac

Companies Reporting Before The Bell • Passage Bio (NASDAQ:PASG) is estimated to report earnings for its fourth quarter. • Precigen (NASDAQ:PGEN) is projected to report quarterly loss at $0.10 per share on revenue of $6.21 million. • Quanterix (NASDAQ:QTRX) is projected to report quarterly loss at $0.47 per share on revenue of $25.78 million. • Lordstown Motors (NASDAQ:RIDE) is estimated to report quarterly loss at $0.27 per share on revenue of $1.29 million. • Adaptimmune Therapeutics (NASDAQ:ADAP) is projected to report quarterly loss at $0.25 per share on revenue of $4.12 million. • Biodesix (NASDAQ:BDSX) is likely to report earnings for its fourth quarter. • Quantum-Si (NASDAQ:QSI)